Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

395 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting TRAIL agonistic receptors for cancer therapy.
Carlo-Stella C, Lavazza C, Locatelli A, Viganò L, Gianni AM, Gianni L. Carlo-Stella C, et al. Among authors: gianni am, gianni l. Clin Cancer Res. 2007 Apr 15;13(8):2313-7. doi: 10.1158/1078-0432.CCR-06-2774. Clin Cancer Res. 2007. PMID: 17438088 Review.
Anthracyclines.
Gianni L, Grasselli G, Cresta S, Locatelli A, Viganò L, Minotti G. Gianni L, et al. Cancer Chemother Biol Response Modif. 2002;20:59-69. Cancer Chemother Biol Response Modif. 2002. PMID: 12703200 Review. No abstract available.
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Viganò L, Fumagalli M, Ménard S, Gianni L. Campiglio M, et al. Among authors: gianni l. J Cell Physiol. 2004 Feb;198(2):259-68. doi: 10.1002/jcp.10411. J Cell Physiol. 2004. PMID: 14603528
Anthracyclines.
Gianni L, Grasselli G, Cresta S, Locatelli A, Viganò L, Minotti G. Gianni L, et al. Cancer Chemother Biol Response Modif. 2003;21:29-40. Cancer Chemother Biol Response Modif. 2003. PMID: 15338739 Review. No abstract available.
Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez Lopez JJ, Mansutti M, Valagussa P, Bonadonna G; European Cooperative Trial in Operable Breast Cancer Study Group. Gianni L, et al. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8715-21. doi: 10.1158/1078-0432.CCR-05-0539. Clin Cancer Res. 2005. PMID: 16361558 Clinical Trial.
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Perotti A, Locatelli A, Sessa C, Hess D, Viganò L, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F, Gianni L. Perotti A, et al. Among authors: gianni l. J Clin Oncol. 2010 Oct 20;28(30):4554-61. doi: 10.1200/JCO.2009.27.5867. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855840 Clinical Trial.
395 results